Unlocking the Commercial Potential of Psychedelics
PSYCH is a data and insights platform for the psychedelic healthcare industry.
The Psychedelics as Medicine Report: Third Edition
The leading resource for comprehensive insight and
intelligence on the global psychedelics industry.
Follow us on Twitter
';
The Psychedelics Newsletter tracks key players, innovations and milestones to identify emerging opportunities.
With over 25,000 subscribers, the industry's best read newsletter empowers investors to make informed decisions.
Complimentary subscription: https://bit.ly/3baIGDy
‘Demand for NHS services has skyrocketed over the last two years with the pandemic taking a significant toll on the nation’s wellbeing.’
@ClaireCNWL on @NHSuk expanding children’s mental health services 40%, as 22,000 roles remain unfilled: https://bit.ly/3vR9cws
25% of health practitioners believe psychedelic-assisted therapy should be available on @NHSuk.
The Psychedelics as Medicine Report contains 200+ pages of industry intelligence, so investors can make informed decisions.
Complimentary download: https://psych.global/report
'Every step forward for psychedelics anywhere in the world helps every other jurisdiction that wants to legalise.'
@SSinghal, a supporter of @UHNfoundation which partners with @MAPS, spoke with @Business on the regulation of psilocybin in Canada: https://bloom.bg/3BPK1Os
Kernel Flow provides quantifiable neuroimaging data, empowering researchers to measure the efficacy of psychedelic medicines in real-time.
@KernelCo's CTO, Ryan Field, discussed how the headset accelerates innovation at the sold out PSYCH Symposium: https://youtu.be/64tRd52lFaM $CYBN